Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer

Guoshun Luo(China Pharmaceutical University), Hua Xiang(Southwest Minzu University), Xin Wang(Clemson University), Luyu Ma(China Pharmaceutical University), Shengnan Ren(Second Affiliated Hospital of Nanjing Medical University), Shuangjie Wu(China Pharmaceutical University), Xin Lin(Central South University)
European Journal of Medicinal Chemistry
September 27, 2021
Cited by 20


Related Papers